Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Results: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib and blinatumomab in relapsed or refractory adult B-ALL, including Philadelphia chromos…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL [NA]
Clinical trial update on using chemotherapy with targeted immunotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphobla…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating whether adding ponatinib to dose-adjusted EPOCH, with or without rituximab, improves outcomes in newly d…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase I/II clinical trial is evaluating the combination of blinatumomab and asciminib in adults with Philadelphia chromosome-positive acut…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update evaluating the combination of blinatumomab with a tyrosine kinase inhibitor in Philadelphia chromosome-positiv…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) [Phase 2]
A Phase 2 study evaluating a chemotherapy-free induction regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia using ino…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL [Phase 1]
Phase 1 trial evaluating asciminib as maintenance therapy after allo-HCT or CAR T to prevent relapse in adults with Philadelphia chromosome-…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML [Phase 2]
Phase 2 clinical trial evaluating asciminib in combination with standard-of-care as maintenance therapy after allogeneic stem cell transplan…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) [Phase 2]
Phase II clinical trial evaluating the combination of subcutaneous blinatumomab and olverembatinib for Philadelphia chromosome-positive and/…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia [Phase 2]
A Phase 2 clinical trial is investigating the addition of asciminib to standard treatment for adults with newly diagnosed Philadelphia chrom…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL [Phase 2]
A Phase 2 trial assesses the efficacy and safety of combining olverembatinib with inotuzumab ozogamicin as a first-line consolidation therap…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL [NA]
An ongoing clinical trial evaluating a tyrosine kinase inhibitor combined with chemotherapy and sequential CAR-T cell therapy in newly diagn…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
This clinical trial update discusses long-term progression of patients treated for relapsed or refractory Philadelphia chromosome–positive a…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 clinical trial evaluating imatinib mesylate in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive ac…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating dasatinib in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leuk…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia [Phase 1]
A Phase 1 clinical trial sponsored by OHSU Knight Cancer Institute is evaluating a five-drug combination (venetoclax, dasatinib, prednisone,…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]
This article outlines a Phase 1/2 clinical trial evaluating the safety and efficacy of asciminib in pediatric and young adult patients with …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
This clinical trial update aims to assess the real-world efficacy of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leuke…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL [Phase 2]
Phase 2 clinical trial assessing subcutaneous blinatumomab in combination with ponatinib for Philadelphia chromosome-positive BCR-ABL–positi…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase 1/2 trial of ADCT-602 for recurrent or refractory B-cell acute lymphoblastic leukemia has been terminated.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Multicenter Study of CAR-T Cells in Primary Ph+All [Phase 2]
A multicenter Phase 2 clinical trial evaluating CAR-T cell therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia is curr…
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Dr. Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' generic nilotinib under an Original Application (ANDA). It is indicated for chronic myeloid leukemia …
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (AvKARE)
FDA approved AvKARE's nilotinib original application, authorizing a generic version of nilotinib for leukemia indications.
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic nilotinib product. The generic is intended to treat certain Philadel…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies [Phase 1]
A Phase 1 study from Stanford is evaluating CD19/CD22 CAR T cells with or without NKTR-255 in adults with recurrent or refractory B-cell mal…